Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas Academic Article uri icon

Overview

MeSH Major

  • Hodgkin Disease
  • Immunoconjugates
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, T-Cell

abstract

  • Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study. Treatment was associated primarily with grade 1 or 2 (mild-to-moderate) toxic effects. (Funded by Seattle Genetics; ClinicalTrials.gov number, NCT00430846.).

publication date

  • November 4, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1002965

PubMed ID

  • 21047225

Additional Document Info

start page

  • 1812

end page

  • 21

volume

  • 363

number

  • 19